All News

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

A recent study found that indoor allergen exposure, including mouse and cockroach allergens, led to an increased risk of respiratory viral infections in children with asthma.

The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.

The AHA acknowledged that complementary and alternative medicines are widely used by heart failure patients but warned that there is limited scientific evidence to support their efficacy.

Ustekinumab is a human monoclonal antibody targeting the cytokines interleukin (IL)-12 and IL-23, which play a rule in the inflammatory and immune responses.

Approximately 75% of adults trust their physicians, nurses, and pharmacists either a great deal or a lot, highlighting the importance of pharmacists for patient education.

Karen Merrill discusses her experiences in pharmacy with plans to celebrate her niece, a first-year pharmacist.

MDL-101 is a proposed novel precision medicine that targets the LAMA1 gene, causing LAMA2 congenital muscular dystrophy type 1a.

The guidelines mark a shift in practice by recommending a multimodal approach to opioid prescribing practices.

There was a detrimental relationship between COVID-19 caseload and mortality observed across multiple types of hospitals.

C. diff survivor and Peggy Lillis Foundation Board Member Maryann Webb discusses how her experience with the infection encouraged her to advocate for patients who are struggling to advocate for themselves.

Poorer prognosis was linked to factors such as reduced hemoglobin levels and advanced stage at diagnosis.

The survey demonstrated that adolescents and young adults (AYAs) who preferred health care professionals (HCPs) as sources of information had sufficient knowledge of contraception options available.

Although the investigators commonly detected treatment-emergent resistant variants, they were rare and transient in nature.

Brooke Peters, PharmD, BCOP, discusses a study conducted at American Oncology Network (AON) to evaluate luspatercept dosing for patients with low- to intermediate-risk myelodysplastic syndromes (MDS).

Alan Corley, pharmacy owner in Greenville, TN, reflects on the changes he's witnessed throughout his career and the most rewarding aspects of his profession.

Aaron Adkisson, PharmD, discusses the importance of considering factors such as age, gender, and cardiovascular comorbidities when monitoring and managing cardiotoxic risks in patients with cancer. also emphasizing patient education on recognizing early heart failure symptoms.

Currently, the CDC recommends the recombinant zoster vaccine (Shingrix, RZV; GSK) for the prevention of herpes zoster and related complications.

Small molecule agents continue to be beneficial additions to multiple myeloma treatment, even with the development of T-cell redirected therapies.

These interim trial results support the ongoing phase 3 ITHACA trial.

Experts discuss emerging targets in the immunotherapy landscape and how to improve patient outcomes through innovative approaches.

Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.

Ashraf Badros, MBCHB, discussed new data from the AURIGA study presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Experts discuss immunotherapy advancements and challenges of resistance, efficacy, and toxicity in patient management.

The trial is evaluating ciltacabtagene autoleucel (cilta-cel, Carvykti; Johnson & Johnson) in patients with relapsed and lenalidomide-refractory multiple myeloma.

The indication is for adult and pediatric patients aged 2 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC) who require systemic therapy.

Minimal residual disease has been a major topic of discussion during the IMS 2024 Annual Meeting.

Ashraf Badros, MBCHB, discussed findings from the AURIGA study being presented at the International Myeloma Society 2024 Annual Meeting, happening September 25 through 29 in Rio de Janeiro, Brazil.

Promising depth of response and consistent safety profile support the use of talquetamab as a combination agent.

The estimated vaccine efficacy was approximately 58%, with only 21 patients in the vaccinated group being diagnosed with mpox.